TVGN Stock Summary and Trading Ideas (Tevogen Bio Holdings | NASDAQ:TVGN)

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Tevogen Bio Holdings trades on the NASDAQ stock market under the symbol TVGN.

As of April 24, 2026, TVGN stock price climbed to $7.20 with 7,844 million shares trading.

TVGN has a beta of 2.54, meaning it tends to be more sensitive to market movements. TVGN has a correlation of 0.13 to the broad based SPY ETF.

TVGN has a market cap of $29.15 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that TVGN belongs to (by Net Assets): VTI, IWM, IWC, IWO, VTWO.

TVGN has underperformed the market in the last year with a return of -85.9%, while the SPY ETF gained +34.7%. In the last 3 month period, TVGN fell short of the market, returning -58.8%, while SPY returned +3.8%. However, in the most recent 2 weeks TVGN has outperformed the stock market by returning +22.9%, while SPY returned +5.0%.

TVGN support price is $6.35 and resistance is $7.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TVGN shares will trade within this expected range on the day.